Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person8
Bionano Genomics, Inc.
Company
10x Genomics, Inc.
Company
NEOGENOMICS INC
Company
Beta Bionics, Inc.
Company
BIOGEN INC.
Company
GRI Bio, Inc.
Company
Opus Genetics, Inc.
Company
HCW Biologics Inc.
Company
Primary record7
Bionano Genomics, Inc. filed S-1
SEC form S-1 filed by Bionano Genomics, Inc. (CIK 1411690) on 2026-10-27.
Bionano Genomics, Inc. filed SCHEDULE 13G
pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"): (i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shar
Bionano Genomics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 14, 2026, Al Luderer, Ph.D., Chairman and Interim Chief Executive Officer of Bionano Genomics, Inc. (the Company ), is presenting at the H.C. Wainwright 28th Annual Global
Bionano Genomics, Inc. filed 4
SEC form 4 filed by Bionano Genomics, Inc. (CIK 1411690) on 2026-09-09.
Bionano Genomics, Inc. filed 4
SEC form 4 filed by Bionano Genomics, Inc. (CIK 1411690) on 2026-08-21.
Bionano Genomics, Inc. filed SCHEDULE 13G/A
0001649553-26-000099.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001649553-26-000022 0001649553 XXXXXXXX LIVE 2 Common Stock, $0.0001 par value per share 06/30/2026 0001411690 Bionano Genomics,
Bionano Genomics, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Bionano Genomics, Inc. (the Company ) issued a press release reporting its financial results for the second quarter ended June 30, 2026. The fu